- Home
- SMTI vs DMAC Comparison
SMTI vs DMAC Comparison
Compare SMTI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- DMAC
- Stock Information
- Founded
- SMTI 1982
- DMAC 2000
- Country
- SMTI United States
- DMAC United States
- Employees
- SMTI N/A
- DMAC N/A
- Industry
- SMTI Medical/Dental Instruments
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SMTI Health Care
- DMAC Health Care
- Exchange
- SMTI Nasdaq
- DMAC Nasdaq
- Market Cap
- SMTI 252.1M
- DMAC 178.0M
- IPO Year
- SMTI N/A
- DMAC N/A
- Fundamental
- Price
- SMTI $29.65
- DMAC $3.76
- Analyst Decision
- SMTI Strong Buy
- DMAC Strong Buy
- Analyst Count
- SMTI 2
- DMAC 2
- Target Price
- SMTI $49.50
- DMAC $8.00
- AVG Volume (30 Days)
- SMTI 45.1K
- DMAC 307.4K
- Earning Date
- SMTI 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- SMTI N/A
- DMAC N/A
- EPS Growth
- SMTI N/A
- DMAC N/A
- EPS
- SMTI N/A
- DMAC N/A
- Revenue
- SMTI $91,569,883.00
- DMAC N/A
- Revenue This Year
- SMTI $23.53
- DMAC N/A
- Revenue Next Year
- SMTI $5.93
- DMAC N/A
- P/E Ratio
- SMTI N/A
- DMAC N/A
- Revenue Growth
- SMTI 34.65
- DMAC N/A
- 52 Week Low
- SMTI $25.86
- DMAC $2.80
- 52 Week High
- SMTI $39.08
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SMTI 54.56
- DMAC 47.18
- Support Level
- SMTI $28.00
- DMAC $3.48
- Resistance Level
- SMTI $30.59
- DMAC $3.99
- Average True Range (ATR)
- SMTI 1.22
- DMAC 0.32
- MACD
- SMTI 0.27
- DMAC -0.00
- Stochastic Oscillator
- SMTI 74.93
- DMAC 41.01
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.